ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

825,000 Pounds of Yew Bark Clleced in ’91 For 10,000 Patients

March 13, 1992

FDA Committee Agenda Includes M-AMSA, THC, Estramustine, Platinum

May 22, 1981

Officals: “Separations” in Normal Range as Critics Claim Brain Drain in the Clinic

January 17, 2014

Toxicity Testing Reorganization Announced; Rall To Head It Up

November 17, 1978

NCAB Calls For Modification Of Rules For NIH Scientist-Industry Collaboration

December 10, 2010

Digital Immunoassay PSA Test May Predict Cancer Recurrence

October 28, 2011